Hints and tips:
...In other deal news: Roche announced earlier today that it is planning to buy immunology company Telavant from Roivant Sciences and Pfizer for more than $7bn. 2....
...These are the components of the Granolas: GSK, Roche, ASML, Nestlé, Novartis, Novo Nordisk, L’Oréal, LVMH, AstraZeneca, SAP, Sanofi. Trips off the tongue, right? Granolas....
...Smart reads The Takedown Kyle Roche ran a law firm with a leading reputation in the fast-growing field of cryptocurrency litigation....
...In July, two of the biggest antibody tests supplied to the UK — Abbott’s and Roche’s — were found not to meet the government’s own requirements....
...So far, only a few tests have been endorsed by Public Health England — including Abbott and Roche’s — despite lobbying from a wide range of manufacturers....
...New chief executive Roland Diggelmann — a non-executive director and former chief executive of Roche Diagnostics — will have his pay amended in line with the new policy, when approved....
...EU institutions would have needed to use a local broker to access some of Europe’s most actively traded stocks, such as Nestlé, Novartis and Roche, while Swiss investors would have to go through EU banks...
...Roche’s planned $4.8bn acquisition of Spark Therapeutics, a US gene therapy group, may be delayed beyond this quarter after US regulators demanded more information about the deal....
...They remain actively involved through Jim Sharp, a non-executive director, who is married to Isabel Mary Brunner, the great granddaughter of Sir John Brunner....
...He added that in his opinion, just three companies — GlaxoSmithKline, Roche and Shionogi — were active in the field....
...Just three companies — GlaxoSmithKline, Roche and Shionogi — are active in the field....
...The medicines, which wowed the audience at Asco in 2014, raked in $10bn in sales last year for Merck of the US, Bristol-Myers Squibb, Roche and AstraZeneca....
...cent stake in its consumer joint venture with GlaxoSmithKline; whether to spin out Alcon, its eyecare unit; and whether to sell its longstanding stake, amounting to 6 per cent of outstanding shares, in Roche...
...Click here to find out how Jim Sullivan, head of pharmaceuticals discovery at AbbVie, goes for underactivity....
...Two hotels closed and a lot of small business suffered when mining tailed off,” says Jim Nugent, owner of Nugent’s Food Store in the small town of 1,500 people in central Queensland....
...The top five drugmakers by market capitalisation — Johnson & Johnson, Roche, Novartis, Pfizer and Merck — were among more than 80 pharmaceuticals and diagnostics companies that signed the call for collective...
...Roche, president of the state’s Business and Industry Association....
...The company was acquired by Roche, the Swiss drugs and diagnostics group, in August in a deal worth up to $425m. However, while technology is advancing there are economic barriers to adoption....
...Roche and GlaxoSmithKline, two of the world’s biggest drugmakers, on Thursday promised to work with the commission on its ideas — without making firm financial commitments....
...Sceptical welcome The idea of unleashing the immune system to tackle cancer dates back several decades, but the emergence of this generation of drugs is due above all to the persistence of Jim Allison,...
...Roche, the Swiss healthcare group, has raised its full-year outlook....
...Merck of the US in December agreed to pay $9.5bn for Cubist, an antibiotics specialist, and Roche of Switzerland has returned to the field....
...Roche, Johnson & Johnson, and Biogen Idec have all joined Shire — which is paying $5.2bn for NPS Pharmaceuticals — in announcing major acquisitions....
...But there have been signs of a revival in the past two years, with Roche, GlaxoSmithKline and Sanofi all pledging fresh investment or forging research partnerships to develop new bug-fighting drugs....
...Sanofi of France and Roche of Switzerland have both taken steps in the past year to increase investment....
International Edition